Notice of AGM

RNS Number : 8259G
Epistem Holdings plc
24 November 2015
 



 

RNS Press Release

For release: 24 November 2015

 

2015 Annual Report and Accounts & AGM Notification

 

Epistem Holdings Plc (LSE: EHP) ("Epistem" or "the Company"), the personalised medicine and biotechnology company, today gives notice that copies of its 2015 Annual Report and the Notice of the Annual General Meeting ("AGM") dated 23 November 2015 have been sent out to shareholders.

 

Copies of these documents can be found on the Company's website (www.epistem.co.uk).

 

The AGM will be held at 11am on Wednesday 16th December, 2015 at the offices of 41 Lothbury, London, EC2R 7HG.

 

For further details please contact:

Epistem Holdings Plc

Dr Ian Gilham: Chairman                                                                                       +44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                                +44 (0)207 418 8900

Tom Burt

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner / Laura Thornton                                                                          +44 (0)203 709 5700

epistem@consilium-comms.com 

 

 

Notes to Editors

 

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Genedrive® provides a major advance in molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity and specificity for the diagnostics of infectious diseases and for use in patient stratification (genotyping). Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the India sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOAFEIFILFISEEF

Companies

Genedrive (GDR)
UK 100

Latest directors dealings